Search Results - "Dalla Palma, Benedetta"
-
1
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
Published in BioMed research international (01-01-2015)“…Multiple myeloma (MM) is characterized by a high capacity to induce alterations in the bone remodeling process. The increase in osteoclastogenesis and the…”
Get full text
Journal Article -
2
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
Published in Journal of clinical medicine (19-09-2020)“…B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, is universally expressed by normal and neoplastic plasma cells…”
Get full text
Journal Article -
3
-
4
Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
Published in Cancers (06-03-2019)“…C-X3-C motif chemokine ligand 1 (CX3CL1)/fractalkine is a chemokine released after cleavage by two metalloproteases, ADAM metallopeptidase domain 10 (ADAM10)…”
Get full text
Journal Article -
5
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies
Published in Journal of clinical medicine (04-09-2020)“…The monoclonal antibodies (mAbs) have significantly changed the treatment of multiple myeloma (MM) patients. However, despite their introduction, MM remains an…”
Get full text
Journal Article -
6
New Insights into Osteogenic and Chondrogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells and Their Potential Clinical Applications for Bone Regeneration in Pediatric Orthopaedics
Published in Stem Cells International (01-01-2013)“…Human mesenchymal stem cells (hMSCs) are pluripotent adult stem cells capable of being differentiated into osteoblasts, adipocytes, and chondrocytes. The…”
Get full text
Journal Article -
7
CD38 expression by plasma cells in extramedullary multiple myeloma
Published in Haematologica (Roma) (01-04-2024)Get full text
Journal Article -
8
Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation
Published in EJHaem (01-08-2024)“…A portion of multiple myeloma (MM) patients relapse early or do not respond to first line treatment. Identification of possible clinical and or biological…”
Get full text
Journal Article -
9
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Published in Cells (Basel, Switzerland) (13-12-2019)“…In the last decades CD38 has emerged as an attractive target for multiple myeloma (MM). CD38 is a novel multifunctional glycoprotein that acts as a receptor,…”
Get full text
Journal Article -
10
-
11
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis
Published in Case reports in hematology (01-01-2018)“…Muscle involvement in AL amyloidosis is a rare condition, and the diagnosis of amyloid myopathy is often delayed and underdiagnosed. Amyloid myopathy may be…”
Get full text
Journal Article -
12
Neurofibromatosis type I and multiple myeloma coexistence: A possible link?
Published in Hematology reports (03-04-2018)“…The association between Neurofibromatosis type I (NF1) and multiple myeloma (MM), a plasma cell, dyscrasia is very rare. Here we put to the attention of the…”
Get full text
Journal Article -
13
CD14+CD16+ monocytes are involved in daratumumab‐mediated myeloma cells killing and in anti‐CD47 therapeutic strategy
Published in British journal of haematology (01-08-2020)“…Summary A deep elucidation of the mechanisms of action of anti‐CD38 monoclonal antibodies (mAbs), such as daratumumab (DARA), is required to identify patients…”
Get full text
Journal Article -
14
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors
Published in Journal of bone and mineral research (01-04-2016)“…ABSTRACT Multiple myeloma (MM) is characterized by severely imbalanced bone remodeling. In this study, we investigated the potential effect of proteasome…”
Get full text
Journal Article -
15
-
16
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results
Published in Frontiers in immunology (03-02-2021)“…Maintenance treatment after autologous bone marrow transplantation in multiple myeloma improves the outcome of patients. We designed a phase II clinical trial…”
Get full text
Journal Article -
17
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
Published in Cancers (05-11-2020)“…Multiple myeloma (MM) cells consume huge amounts of glutamine and, as a consequence, the amino acid concentration is lower-than-normal in the bone marrow (BM)…”
Get full text
Journal Article -
18
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
Published in Oncoimmunology (31-12-2022)“…The humoral and cellular response to SARS-CoV-2 mRNA full vaccination and booster dose as well as the impact of the spike variants, including Omicron, are…”
Get full text
Journal Article -
19
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
Published in Frontiers in immunology (08-01-2021)“…The PD-1/PD-L1 axis has recently emerged as an immune checkpoint that controls antitumor immune responses also in hematological malignancies. However, the use…”
Get full text
Journal Article -
20
Bone marrow Dikkopf‐1 levels are a new independent risk factor for progression in patients with smouldering myeloma
Published in British journal of haematology (01-12-2018)Get full text
Journal Article